Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they pot...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/532 |
| _version_ | 1797618767218343936 |
|---|---|
| author | Sven Schnichels David Simmang Marina Löscher Andreas Herrmann Jan Willem de Vries Martin S. Spitzer José Hurst |
| author_facet | Sven Schnichels David Simmang Marina Löscher Andreas Herrmann Jan Willem de Vries Martin S. Spitzer José Hurst |
| author_sort | Sven Schnichels |
| collection | DOAJ |
| description | Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies. |
| first_indexed | 2024-03-11T08:17:14Z |
| format | Article |
| id | doaj.art-b767bbd8b6b744e69d920dcf31efd830 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:17:14Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-b767bbd8b6b744e69d920dcf31efd8302023-11-16T22:41:12ZengMDPI AGPharmaceutics1999-49232023-02-0115253210.3390/pharmaceutics15020532Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal DiseasesSven Schnichels0David Simmang1Marina Löscher2Andreas Herrmann3Jan Willem de Vries4Martin S. Spitzer5José Hurst6Centre for Ophthalmology, University Eye Hospital Tübingen, 72076 Tübingen, GermanyCentre for Ophthalmology, University Eye Hospital Tübingen, 72076 Tübingen, GermanyCentre for Ophthalmology, University Eye Hospital Tübingen, 72076 Tübingen, GermanyDWI—Leibniz Institute for Interactive Materials, Forckenbeckstr. 50, 52056 Aachen, GermanyCentre for Ophthalmology, University Eye Hospital Tübingen, 72076 Tübingen, GermanyUniversity Eye Hospital Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, GermanyCentre for Ophthalmology, University Eye Hospital Tübingen, 72076 Tübingen, GermanyRetinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies.https://www.mdpi.com/1999-4923/15/2/532retinadrug-deliverylipid-DNA nanoparticlesfluorophotometrybiodegradableintravitreal injection |
| spellingShingle | Sven Schnichels David Simmang Marina Löscher Andreas Herrmann Jan Willem de Vries Martin S. Spitzer José Hurst Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases Pharmaceutics retina drug-delivery lipid-DNA nanoparticles fluorophotometry biodegradable intravitreal injection |
| title | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
| title_full | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
| title_fullStr | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
| title_full_unstemmed | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
| title_short | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
| title_sort | lipid dna nanoparticles as drug delivery vehicles for the treatment of retinal diseases |
| topic | retina drug-delivery lipid-DNA nanoparticles fluorophotometry biodegradable intravitreal injection |
| url | https://www.mdpi.com/1999-4923/15/2/532 |
| work_keys_str_mv | AT svenschnichels lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT davidsimmang lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT marinaloscher lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT andreasherrmann lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT janwillemdevries lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT martinsspitzer lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT josehurst lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases |